Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 10/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TXN | P10599 | 1/20 | 0.41 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL14645279 | 0.98 | TERT (0.46) | TERTTAAR1TBXAS1ALOX15TXN | |
| SCHEMBL441515 | 0.88 | TBXAS1 (0.49) | TERTTAAR1TBXAS1ALOX15TXN | |
| SCHEMBL439546 | 0.86 | TBXAS1 (0.51) | TERTTAAR1TBXAS1ALOX15TXN | |
| SCHEMBL4129898 | 0.85 | TBXAS1 (0.54) | TERTTAAR1TBXAS1ALOX15TXN | |
| SCHEMBL27232031 | 0.85 | TBXAS1 (0.54) | TERTTAAR1TBXAS1ALOX15TXN | |
| SCHEMBL4511723 | 0.84 | TERT (0.44) | TERTTAAR1TBXAS1ALOX15TXN | |
| SCHEMBL22193258 | 0.84 | TERT (0.44) | TERTTAAR1TBXAS1ALOX15TXN | |
| SCHEMBL28802161 | 0.82 | TXN (0.45) | TERTTAAR1TBXAS1ALOX15TXN | |
| SCHEMBL31414953 | 0.81 | TERT (0.42) | TERTTAAR1TBXAS1ALOX15TXN | |
| SCHEMBL19185709 | 0.81 | TERT (0.42) | TERTTAAR1TBXAS1ALOX15TXN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638031-B9 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2020-01-08 | — | — | EP | claimed |
| EP-2638031-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-10-11 | — | — | EP | claimed |
| EP-3124483-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-02-01 | — | — | EP | claimed |
| US-8815882-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | claimed |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-10981894-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10736881-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-07-09 | — | — | US | disclosed |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20100256138-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2010-10-07 | — | — | US | disclosed |
| US-7781595-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2010-08-24 | — | — | US | disclosed |
| US-7781595-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2010-08-24 | — | — | US | disclosed |
| US-20090023933-A1 | METHOD FOR ISOLATING ACIDS FROM CHEMICAL REACTION MIXTURES BY USING 1-ALKYLIMIDAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20070043043-A1 | Benzimidazole derivates: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2007-02-22 | — | — | US | disclosed |
| US-20070043043-A1 | Benzimidazole derivates: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2007-02-22 | — | — | US | disclosed |
| CN-1894174-A | Method for isolating acids from chemical reaction mixtures by using 1-alkylimidazoles | BASF AG (DE) | 2007-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | TERT 4247/4885TAAR1 247/4885TBXAS1 2048/4885 |
| US-20070043043-A1 | Benzimidazole derivates: preparation and pharmaceutical applications | HDAC5, HDAC1, HDAC4 | TERT 2591/4885TAAR1 4735/4885TBXAS1 2925/4885 |
| US-10736881-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | HDAC5, HDAC1, HDAC8 | TERT 2540/4885TAAR1 4762/4885TBXAS1 2751/4885 |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | TERT 4247/4885TAAR1 247/4885TBXAS1 2048/4885 |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | TERT 4247/4885TAAR1 247/4885TBXAS1 2048/4885 |
| US-20100256138-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | TERT 2540/4885TAAR1 4762/4885TBXAS1 2751/4885 |
| US-20090023933-A1 | METHOD FOR ISOLATING ACIDS FROM CHEMICAL REACTION MIXTURES BY USING 1-ALKYLIMIDAZOLES | POLL, INO80C, BRD7 | TERT 1193/4885TAAR1 2735/4885TBXAS1 2094/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | TERT 1263/4885TAAR1 1575/4885TBXAS1 1025/4885 |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | TERT 4247/4885TAAR1 247/4885TBXAS1 2048/4885 |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | TERT 4247/4885TAAR1 247/4885TBXAS1 2048/4885 |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | TERT 4247/4885TAAR1 247/4885TBXAS1 2048/4885 |
| US-10981894-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | TERT 4247/4885TAAR1 247/4885TBXAS1 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.